相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors
Michael Kilian et al.
CANCER CELL (2023)
GD2-CART cell therapy for H3K27M-mutated diffuse midline gliomas
Robbie G. Majzner et al.
NATURE (2022)
The prognostic significance of HIST1H3B/C and H3F3A K27M mutations in diffuse midline gliomas is influenced by patient age
Huy Gia Vuong et al.
JOURNAL OF NEURO-ONCOLOGY (2022)
The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location
Ilon Liu et al.
NATURE GENETICS (2022)
K27M in canonical and noncanonical H3 variants occurs in distinct oligodendroglial cell lineages in brain midline gliomas
Selin Jessa et al.
NATURE GENETICS (2022)
H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma
Lena Immisch et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
A vaccine targeting mutant IDH1 in newly diagnosed glioma
Michael Platten et al.
NATURE (2021)
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
NEURO-ONCOLOGY (2021)
Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial
David A. Reardon et al.
CLINICAL CANCER RESEARCH (2020)
Mechanisms and therapeutic implications of hypermutation in gliomas
Mehdi Touat et al.
NATURE (2020)
Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience
Chantel Cacciotti et al.
JOURNAL OF NEURO-ONCOLOGY (2020)
Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma
Sabine Mueller et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma
Stephanie L. Goff et al.
JOURNAL OF IMMUNOTHERAPY (2019)
The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models
Naiara Martinez-Velez et al.
NATURE COMMUNICATIONS (2019)
Analysis of PD-L1 expression and T cell infiltration in different molecular subgroups of diffuse midline gliomas
Prerana Jha et al.
NEUROPATHOLOGY (2019)
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
Antonio Omuro et al.
NEURO-ONCOLOGY (2018)
Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells
Mara Vinci et al.
NATURE MEDICINE (2018)
Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate
Lukas Bunse et al.
NATURE MEDICINE (2018)
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
Michael Weller et al.
LANCET ONCOLOGY (2017)
K27M-mutant histone-3 as a novel target for glioma immunotherapy
Katharina Ochs et al.
ONCOIMMUNOLOGY (2017)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas
Martin J. van den Bent et al.
NEURO-ONCOLOGY (2015)
Diffuse intrinsic pontine glioma: a reassessment
Nathan J. Robison et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
A vaccine targeting mutant IDH1 induces antitumour immunity
Theresa Schumacher et al.
NATURE (2014)
Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas
Sebastian Bender et al.
CANCER CELL (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Thalamic high-grade gliomas in children: a distinct clinical subset?
Christof M. Kramm et al.
NEURO-ONCOLOGY (2011)